Professor Chris Twelves, clinical director at the Leeds Teaching Hospitals NHS Trust NIHR Leeds CRF and Professor of Clinical Cancer Pharmacology and Oncology at the University of Leeds said: “This investigational cancer vaccine works by training the immune system to fight the cancer, which could be transformational for patients by slowing spread of the cancer and hopefully controlling their disease for longer.
Trending
- Enrollment Begins for Elritercept Phase 3 Trial in Lower-Risk MDS
- Cancer cases could surge 67% worldwide by 2050
- Early statin use linked to 15% lower dementia risk
- From Hyper-Independent to Human: Learning How to Accept Help
- How Northern Ireland can save almost 6,000 lives from cancer – Cancer Research UK
- Scientists find a new weakness in treatment-resistant prostate cancer
- Goal-Based Nutrition Support May Not Limit Muscle Loss in Esophageal Cancer
- Azacitidine/Venetoclax Boosts Event-Free Survival in Induction-Eligible AML
Tuesday, September 8
